Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    wo40181
Previous Study | Return to List | Next Study

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03584009
Recruitment Status : Recruiting
First Posted : July 12, 2018
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE June 25, 2018
First Posted Date  ICMJE July 12, 2018
Last Update Posted Date July 7, 2020
Actual Study Start Date  ICMJE September 6, 2018
Estimated Primary Completion Date August 5, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 4, 2019)
Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) lasting >= 24 weeks [ Time Frame: Randomization in patients with measurable disease at baseline through the end of study (2 years after the last patient is enrolled) ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 10, 2018)
Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Sudden Death (SD) lasting >= 24 weeks [ Time Frame: Randomization in patients with measurable disease at baseline through the end of study (2 years after the last patient is enrolled) ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 10, 2018)
  • Progression Free Survival (PFS) [ Time Frame: Randomization to the first occurrence of disease progression as determined by the investigator according to (RECIST v1.1 ) or death from any cause, until the end of study (2 years after the last patient is enrolled) ]
    (RECIST v1.1 ) Response Evaluation Criteria in Solid Tumors Version 1.1
  • Objective Response (OR) [ Time Frame: Objective Response defined as Complete Response (CR) or Partial response (PR), as determined by the investigator according to RECIST v1.1 from Randomization of patient until end of the study (2 years after the last patient enrolled) ]
  • Duration of Response (DOR) [ Time Frame: Time from first occurrence of a documented Objective response to the time of the first documented disease progression or death from any cause, whichever occurs first, until end of the study (2 years after the last patient enrolled) ]
    (as determined by the investigator according to RECIST v1.1)
  • Overall Survival (OS) [ Time Frame: Randomization to death from any cause, through the end of study (2 years after the last patient enrolled) ]
  • Percentage of participants with adverse events [ Time Frame: Baseline to end of study (2 years after the last patient enrolled) ]
  • Plasma concentration of Venetoxclax and fulvestrant [ Time Frame: At pre-defined intervals from Cycle 1, Day 1, through end of treatment (2 years after the last patient enrolled). ]
  • Mean changes from baseline scores in functional disease/treatment-related symptoms and global health status health-related quality of life (GHS/HRQoL) by cycle [ Time Frame: Baseline, cycle 1 day 1, and all subsequent cycles through at the end of treatment/discontinuation visit (2 years after the last patient enrolled) ]
    Mean and mean changes will be assessed by the scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
  • Change in baseline pain score as assessed by the pain scale of EORTC QLQ-C30 [ Time Frame: Baseline through end of study (2 years after the last patient enrolled) ]
  • Baseline BCL-2 protein levels as measured by International Council for Harmonisation (IHC) correlating with clinical response measures [ Time Frame: Baseline through the end of study (2 years after the last patient enrolled) ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Official Title  ICMJE A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Brief Summary This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, inoperable, locally advanced or MBC who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Venetoclax
    Venetoclax will be administered orally, 800-mg tablet beginning on Cycle 1 Day 1
  • Drug: Fulvestrant
    Fulvestrant will be administered orally, 500 mg administered as two 250-mg intramuscular (IM) injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
Study Arms  ICMJE
  • Experimental: Venetoclax + Fulvestrant
    Participants in the venetoclax arm will receive venetoclax, taken orally and fulvestrant administered as IM injections until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last patient is enrolled) which ever occur first.
    Interventions:
    • Drug: Venetoclax
    • Drug: Fulvestrant
  • Active Comparator: Fulvestrant
    Participants will receive fulvestrant administered as IM (intramuscular) injections. No crossover to the venetoclax arm is permitted. Study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last patient is enrolled) which ever occur first.
    Intervention: Drug: Fulvestrant
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 10, 2018)
100
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 5, 2022
Estimated Primary Completion Date August 5, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological confirmation of estrogen receptor-positive (ER+) invasive carcinoma of the breast. ER+, HER2- negative invasive carcinoma of the breast with evaluable sample for BCL-2 IHC value at the time of screening. Participants who were originally diagnosed with HER2-positive breast cancer that converted to HER2-negative MBC are not eligible.
  • Evidence of metastatic or locally advanced disease not amenable to surgical or local therapy with curative intent
  • Be postmenopausal or pre- or perimenopausal women amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin
  • Participants must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one line of treatment must be a CDK4/6i AND participants must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.
  • Participants for whom endocrine therapy (e.g., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at the time of entry into the study, as per national or local treatment guidelines
  • Women of childbearing potential (i.e., not postmenopausal for at least 12 months or surgically sterile) must have a negative serum pregnancy test result at screening, within 14 days prior to the first study drug administration
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods with a failure rate of <1% per year during the treatment period and for 28 days after the last dose of study drug. Women must refrain from donating eggs during this same period.
  • Willing to provide tumor biopsy sample
  • Have at least one measurable lesion via RECIST v1.1
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1
  • Have adequate organ and marrow function
  • Have a life expectancy > 3 months
  • To full fill the coagulation requirements for patient with or without therapeutic anticoagulation

Exclusion criteria:

  • Prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2
  • Pregnant, lactating, or intending to become pregnant during the study
  • Known untreated or active Central Nervous System (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control
  • Prior chemotherapy in the locally advanced or metastatic setting regardless of the duration of the treatment.
  • Any anti-cancer therapy received within 21 days of the first dose of study drug, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, antineoplastic vaccines, or other investigational therapy. (Radiotherapy with palliative intent to non-target sites is allowed).
  • Concurrent radiotherapy to any site or prior radiotherapy within 21 days of Cycle 1 Day 1 or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) or prior radiotherapy to > 25% of bone marrow
  • Current severe, uncontrolled, systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic or infectious disease
  • Any major surgery within 28 days of the first dose of study drug or anticipation of the need for major surgery during the course of study treatment
  • Consumption of one or more of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges including marmalade containing Seville oranges; Star fruit (carambola)
  • Administration within 7 days prior first dose of study treatment of Steroid therapy for anti-neoplastic intent, Strong or moderate CYP3A inhibitors or Strong or moderate CYP3A inducers
  • Need for current chronic corticosteroid therapy (> 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
  • Known infection with (human immunodeficiency virus) HIV or human T-cell leukemia virus 1
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day).
  • Participants who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation. Participants with a past or resolved hepatitis B virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These participants must be willing to undergo monthly DNA testing
  • Positive test results for hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody at screening
  • Active HCV infection, defined as having a positive HCV antibody test at screening
  • History of other malignancies within the past 5 years except for treated skin basal cell carcinoma, squamous cell carcinoma, non-malignant melanoma <= 1.0 mm without ulceration, localized thyroid cancer, or cervical carcinoma in-situ
  • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
  • Cardiopulmonary dysfunction
  • Other medical or psychiatric conditions that, in the opinion of the investigatory, may interfere with the participant's participation in the study
  • Inability or unwillingness to swallow pills or receive intramuscular (IM) injections
  • History of malabsorption syndrome or other condition that would interfere with enteral absorption
  • History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)
  • Concurrent hormone replacement therapy
  • Inability to comply with study and follow-up procedures
  • History or active cardiopulmonary dysfunction
  • Known hypersensitivity to any of the study medications (fulvestrant, venetoclax) or to any of the excipients.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: Female and >= 18 years of age at time of signing Informed Consent Form
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Reference Study ID Number: WO40181 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com
Listed Location Countries  ICMJE Australia,   Canada,   France,   Germany,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03584009
Other Study ID Numbers  ICMJE WO40181
2017-005118-74 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Hoffmann-La Roche
Study Sponsor  ICMJE Hoffmann-La Roche
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP